These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17488540)

  • 1. Results of novel strategies for treatment of Wilms' tumor.
    Tucci S; Cologna AJ; Suaid HJ; Valera ET; Tirapelli LF; Paschoalin EL; Martins AC
    Int Braz J Urol; 2007; 33(2):195-201; discussion 201-3. PubMed ID: 17488540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study.
    Tournade MF; Com-Nougué C; de Kraker J; Ludwig R; Rey A; Burgers JM; Sandstedt B; Godzinski J; Carli M; Potter R; Zucker JM;
    J Clin Oncol; 2001 Jan; 19(2):488-500. PubMed ID: 11208843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.
    Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Acha T; Godzinski J; Oldenburger F; Boccon-Gibod L; Leuschner I; Vujanic G; Sandstedt B; de Kraker J; van Tinteren H; Graf N;
    Lancet; 2015 Sep; 386(9999):1156-64. PubMed ID: 26164096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
    Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy PE; Thomas PR; Kim T; Shochat SJ; Haase GM; Ritchey ML; Kelalis PP; D'Angio GJ
    J Clin Oncol; 1998 Jan; 16(1):237-45. PubMed ID: 9440748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study.
    Pein F; Michon J; Valteau-Couanet D; Quintana E; Frappaz D; Vannier JP; Philip T; Bergeron C; Baranzelli MC; Thyss A; Stephan JL; Boutard P; Gentet JC; Zucker JM; Tournade MF; Hartmann O
    J Clin Oncol; 1998 Oct; 16(10):3295-301. PubMed ID: 9779704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From upfront nephrectomy to preoperative chemotherapy and back: a single institution experience in the treatment of Wilms tumor.
    Sultan I; Masarweh M; Ismael T; Al-Hussaini M; Almousa A; Ali HM; Rodriguez-Galindo C; Ghandour K
    J Pediatr Hematol Oncol; 2009 May; 31(5):333-8. PubMed ID: 19415012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of Wilms' tumour management in two tertiary-care hospitals in Asia.
    Sen S; Kadamba P; Al-AbdulAaly M; Mammen KE; Ahmed S
    Pediatr Surg Int; 1998 Jan; 13(1):42-4. PubMed ID: 9391203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group.
    Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S; Haase G; Ritchey M; Kelalis P; D'Angio GJ
    J Clin Oncol; 1998 Dec; 16(12):3744-51. PubMed ID: 9850017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
    Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
    J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephron-sparing procedures in 11 patients with Wilms' tumor.
    Linni K; Urban C; Lackner H; Höllwarth ME
    Pediatr Surg Int; 2003 Aug; 19(6):457-62. PubMed ID: 12756594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial.
    de Kraker J; Graf N; van Tinteren H; Pein F; Sandstedt B; Godzinski J; Tournade MF;
    Lancet; 2004 Oct 2-8; 364(9441):1229-35. PubMed ID: 15464183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
    Abu-Ghosh AM; Krailo MD; Goldman SC; Slack RS; Davenport V; Morris E; Laver JH; Reaman GH; Cairo MS
    Ann Oncol; 2002 Mar; 13(3):460-9. PubMed ID: 11996479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refining therapeutic strategies for patients with resistant Wilm's tumor.
    Marina NM; Wilimas JA; Meyer WH; Jones DP; Douglass EC; Pratt CB
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):296-300. PubMed ID: 7978044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.
    Green DM; Beckwith JB; Breslow NE; Faria P; Moksness J; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S
    J Clin Oncol; 1994 Oct; 12(10):2126-31. PubMed ID: 7931483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study.
    Pritchard J; Imeson J; Barnes J; Cotterill S; Gough D; Marsden HB; Morris-Jones P; Pearson D
    J Clin Oncol; 1995 Jan; 13(1):124-33. PubMed ID: 7799012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.
    Malogolowkin M; Cotton CA; Green DM; Breslow NE; Perlman E; Miser J; Ritchey ML; Thomas PR; Grundy PE; D'Angio GJ; Beckwith JB; Shamberger RC; Haase GM; Donaldson M; Weetman R; Coppes MJ; Shearer P; Coccia P; Kletzel M; Macklis R; Tomlinson G; Huff V; Newbury R; Weeks D;
    Pediatr Blood Cancer; 2008 Feb; 50(2):236-41. PubMed ID: 17539021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy omitted in the treatment of selected children under 3 years of age with stage III favorable histology Wilms tumor.
    Pachnis A; Pritchard J; Gaze M; Levitt G; Michalski A
    Med Pediatr Oncol; 1998 Sep; 31(3):150-2. PubMed ID: 9722896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Nephroblastoma Treatment According to the SIOP-2001 Strategy at a Single Institution in Argentina.
    Cafferata C; Cacciavillano W; Galluzzo ML; Flores P; Rose A; Zubizarreta P
    J Pediatr Hematol Oncol; 2017 Jan; 39(1):50-55. PubMed ID: 27379530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral Wilms' tumors: single-center experience with 22 cases and literature review.
    Sarhan OM; El-Baz M; Sarhan MM; Ghali AM; Ghoneim MA
    Urology; 2010 Oct; 76(4):946-51. PubMed ID: 20708784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Better survival after combined modality care for adults with Wilms' tumor. A report from the National Wilms' Tumor Study.
    Arrigo S; Beckwith JB; Sharples K; D'Angio G; Haase G
    Cancer; 1990 Sep; 66(5):827-30. PubMed ID: 2167146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.